VectorY Raises $83.5M to Push a TDP-43 Gene Therapy Through ALS
VectorY's €74.5M extension is a runway bet, not a verdict. Two-fifths is an EIB convertible loan, and the ALS trial was tripled to 36 patients before any efficacy data. The readout will decide whether the vector is tolerable, not whether it works.